9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
Shares in Australian biotech Mesoblast dropped by a fifth on Tuesday, after the firm announced the DREAM-HF Phase III trial missed its primary endpoint. 16 December 2020
News of a merger deal for Israel-headquartered pre-clinical biopharma firm Anchiano Therapeutics sent the firm’s shares up as much as 183% early yesterday, and still up 87% at $2.8 by close of trading. 16 December 2020
An amended collaboration agreement will see Gilead Sciences hand back certain rights to Jyseleca (filgotinib), following discouraging feedback from the US regulator. 16 December 2020
China and USA-based Harbour BioMed (HBM) and the Netherlands’ Utrecht University (UU) have licensed their fully human, SARS-CoV-2 neutralizing antibody, 47D11 program, to US pharma major AbbVie for the prevention and treatment of COVID-19 and related coronaviruses. 16 December 2020
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has set a date to discuss BioNTech and Pfizer’s conditional marketing authorization (CMA) application for BNT162b2, a COVID‑19 mRNA vaccine. 15 December 2020
Swiss pharma giant Novartis has announced positive findings from the first interpretable results of the Phase III KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3mg and 6mg in diabetic macular edema (DME). 15 December 2020
Californian investment group Westlake Village BioPartners has launched two new funds totaling $500 million, with the goal of promoting promising firms with innovative technologies. 15 December 2020
Japanese firms Ono Pharmaceutical and Chordia Therapeutics have agreed a licensing deal on CTX-177, the latter company’s MALT1 inhibitor and its related compounds. 15 December 2020
Spanish pharma company Reig Jofre has reached an agreement with Janssen to execute the technology transfer to manufacture its investigational COVID-19 vaccine candidate, Ad26.COV2-S. 15 December 2020
Research from industry analyst GlobalData has found that established players in Japan’s immunology market have a dominant lead in the digital marketing space. 15 December 2020
The US Food and Drug Administration has approved a shorter two-hour infusion time for Ocrevus (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). 15 December 2020
Shares of French metabolic diseases biotech company Poxel closed up 4.1% at 6.62 euros today, after it announced an update on results from the PXL770 Phase IIa STAMP-NAFLD trial in non-alcoholic steatohepatitis (NASH). 14 December 2020
A Phase III study of ruxolitinib in COVID-19 has missed its primary endpoint, with no statistically-significant reduction in severe cases of the disease. 14 December 2020
Messenger ribonucleic acid (mRNA) specialist company CureVac has enrolled the first participant in the pivotal Phase IIb/III study of its vaccine candidate, CVnCoV, against COVID-19. 14 December 2020
The UK life sciences industry has reiterated its commitment to the promise of cell and gene therapies, with representatives across the sector renewing commitments at the 11th Pharmaceutical Industry Network Group (PING) conference. 14 December 2020
The US Food and Drug Administration late Friday issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. 12 December 2020
A key advisory panel of the US medicines regulator has voted in favor of providing Emergency Use Authorization (EUA) for BioNTech and Pfizer’s coronavirus vaccine. 11 December 2020
Japanese drug major Chugai Pharmaceuticals has concluded a license agreement with Swiss giant Roche for the development and commercialization in Japan for the antibody cocktail of casirivimab and imdevimab (formerly known as REGN-COV2) for COVID-19. 11 December 2020
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024